AqueSys raises $35 million
This article was originally published in The Gray Sheet
Executive Summary
Privately held developer of minimally invasive implant technology for glaucoma raises $35 million in a "Series C" private placement led by Longitude Capital and Rho Ventures, announced June 29. With the funding "we are well capitalized to achieve our clinical, regulatory and commercial goals," CEO Ron Bache said